Receives from NIH A Grant of Exclusive Patent License of Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
Acquires China promotion rights of Atom-Hitech (HTA) cardiac imaging agent Technetium (99mTc) Mibi.
Establishes Sinotau Cloud Pharmaceutical Technology Co.,Ltd. to initiate the promotion of radiopharmaceuticals.
Establishes Jiangsu Sinotau Molecular Imaging
Establishes Guangdong Sinotau Molecular Imaging
Sinotau signs license agreement with Piramal Imaging S.A., for development and commercialization of Neuraceq, a novel Aβ amyloid imaging diagnostic agent for Alzheimer’s disease, in China.
SinotauJuly, Sinotau obtains the exclusive patent license for the manufacture of positron-based myocardial perfusion imaging agent [18F] heart ketone injection (MyoZone [18F] Injection).
Sinotau signs exclusive agreement with Cerveau for development and commercialization of MK-6240, the world leading tau protein diagnostic drug for Alzheimer’s disease, in China
Sinotau completes B round financing for 150 million RMB. Qiming Venture Capial is the lead investor. Several Sinotau key employees became shareholders of the company.
Cerveau signs exclusive license agreement with Merck Sharp & Dohme for the global development and commercialization of early stage investigational imaging agent MK-6240.
Sinotau obtains 130 million RMB in A round financing
Sinotau signs exclusive agreement with FluoroPharma Medical Imaging, Inc., an US company, to develop and commercialize cardiac imaging products CardioPET and BFPET in China and Canada.
Sinotau acquires a biological antibody development platform, including CTB006, in the early stages of clinical trials.
Sinotau and Enigma Biomedical Group establishes a US joint venture to form Cerveau Technologies, Inc., in Boston.
Sinotau acquires significant shares of Enigma Biomedical Group, a Canadian company.
Sinotau USA, Inc, a wholly owned subsidiary of Sinotau, is established in Boston.
Sinotau signs an agreement with Navidea Biopharmaceuticals Inc., for the exclusive China distribution rights of Technetium (99mTc) tilmanocept, the first and only receptor-targeted lymphatic mapping agent approved by the FDA.
Sinotau launches several relevant generic products in the Chinese market and becomes a fully vertically integrated company; expanding business operations into R&D, manufacturing, marketing and sales.
Sinotau establishes first cooperation frameworks with overseas multinational pharma players to jointly develop the Chinese market.
Sinotau is founded. Initially it is envisioned as a drug development company.